Skip to main content

Grafa News and Videos — Page 1356

Latest

Grafa

IDEAYA advances darovasertib toward NDA following landmark clinical success

IDEAYA Biosciences (NASDAQ:IDYA) marked a milestone first quarter in 2026, transitioning into a late-stage regulatory company following a decisive clinical win in its lead oncology program and the initiation of a rolling New Drug Application (NDA).

Read more: IDEAYA advances darovasertib toward NDA following landmark clinical success
Grafa

Integra LifeSciences raises profit guidance as management transition takes hold

Integra LifeSciences (NASDAQ:IART) signaled a turning point in its operational recovery today, raising its full-year profit guidance even as it recorded a GAAP loss during a quarter defined by significant leadership changes and supply chain stabilization.

Read more: Integra LifeSciences raises profit guidance as management transition takes hold
Grafa
Technology

Revvity to exit China Immunodiagnostics business as Q1 sales beat estimates

Revvity (NYSE:RVTY) exceeded Wall Street estimates for the first quarter and unveiled a major strategic pivot, announcing its intention to divest its China Immunodiagnostics business to sharpen its focus on high-growth life sciences and specialty diagnostics.

Read more: Revvity to exit China Immunodiagnostics business as Q1 sales beat estimates

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift